About Apnimed, Inc.

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Employees: 65
Price: $22.49
Previous close: $22.49
Market capitalization: $895.62M
Volume: 858,154
52-week low: $16.12
52-week high: $35.29

Additional performance and financial-statement views load in the interactive application.

Market information is provided for research and visualization and is not investment advice.